(Reuters) -AstraZeneca has signed a $555 million deal with a San Francisco-based biotech business Algen Biotechnologies, The Financial Times reported on Monday. The agreement with Algen gives AstraZeneca exclusive rights to develop and commercialise therapies from the Crispr gene-editing technology, the report said. Reuters could not immediately confirm the FT report. (Reporting by Raechel Thankam Job in Bengaluru; Editing by Rashmi Aich)
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
By Tim Hepher PRAGUE (Reuters) -Executives from Boeing and Airbus dampened speculation of imminent decisions…
By Max A. Cherney SAN FRANCISCO (Reuters) -AMD said on Monday it will supply artificial…
Oct 6 (Reuters) - Heathrow: * HEATHROW ANNOUNCES PARTNERSHIP WITH GLOBAL EXCHANGE TO PROVIDE CURRENCY…
VIDEO SHOWS: INTERVIEW WITH FORMER ENGLAND RUGBY UNION CAPTAIN LEWIS MOODY / FILE FOOTAGE OF…
Washington (dpa) - Researchers at the US health centre Penn Medicine have found specific brain circuits…
(Reuters) -Ferrari has completed the construction of e-Vortex, the new test circuit next to its…